ATE345790T1 - Kombination von einem aromatasehemmer mit einem bisphosphonat - Google Patents

Kombination von einem aromatasehemmer mit einem bisphosphonat

Info

Publication number
ATE345790T1
ATE345790T1 AT03766348T AT03766348T ATE345790T1 AT E345790 T1 ATE345790 T1 AT E345790T1 AT 03766348 T AT03766348 T AT 03766348T AT 03766348 T AT03766348 T AT 03766348T AT E345790 T1 ATE345790 T1 AT E345790T1
Authority
AT
Austria
Prior art keywords
bisphosphonate
disease
combination
aromatase
aromatase inhibitor
Prior art date
Application number
AT03766348T
Other languages
English (en)
Inventor
Ajay S Bhatnagar
Dean Brent Evans
Juerg Andreas Gasser
Jonathan Green
Original Assignee
Novartis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0217636A external-priority patent/GB0217636D0/en
Application filed by Novartis Pharma Gmbh filed Critical Novartis Pharma Gmbh
Application granted granted Critical
Publication of ATE345790T1 publication Critical patent/ATE345790T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT03766348T 2002-07-30 2003-07-29 Kombination von einem aromatasehemmer mit einem bisphosphonat ATE345790T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0217636A GB0217636D0 (en) 2002-07-30 2002-07-30 Organic compounds
US42548202P 2002-11-12 2002-11-12

Publications (1)

Publication Number Publication Date
ATE345790T1 true ATE345790T1 (de) 2006-12-15

Family

ID=31497252

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03766348T ATE345790T1 (de) 2002-07-30 2003-07-29 Kombination von einem aromatasehemmer mit einem bisphosphonat

Country Status (12)

Country Link
US (1) US20060069067A1 (de)
EP (1) EP1534265B1 (de)
JP (1) JP2011057706A (de)
CN (1) CN100593401C (de)
AT (1) ATE345790T1 (de)
AU (1) AU2003250190A1 (de)
BR (1) BR0313081A (de)
CA (1) CA2494345C (de)
DE (1) DE60309887T2 (de)
ES (1) ES2276119T3 (de)
PT (1) PT1534265E (de)
WO (1) WO2004012728A1 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0328040D0 (en) * 2003-12-03 2004-01-07 Coleman Robert E Pharmaceutical uses of bisphosphonates
WO2005117864A1 (en) * 2004-05-28 2005-12-15 Astrazeneca Ab Combination product comprising anastrozole and a dual prenyl transferase inhibitor
US20090215731A1 (en) 2005-10-19 2009-08-27 Chavah Pty Ltd. Reduction of Side Effects From Aromatase Inhibitors Used for Treating Breast Cancer
ES2953915T3 (es) 2014-10-22 2023-11-17 Havah Therapeutics Pty Ltd Métodos para reducir la densidad mamaria mamográfica y/o el riesgo de cáncer de mama
CN108472302A (zh) 2015-10-22 2018-08-31 哈瓦赫治疗有限公司 降低乳房摄影乳腺密度和/或乳腺癌风险的方法
EP3454856B1 (de) 2016-05-10 2024-09-11 C4 Therapeutics, Inc. Heterocyclische degronimere für zielproteinabbau
EP3455219A4 (de) 2016-05-10 2019-12-18 C4 Therapeutics, Inc. Amingebundene c3-glutarimiddegronimere für zielproteinabbau
EP3455218A4 (de) 2016-05-10 2019-12-18 C4 Therapeutics, Inc. Mit c3-kohlenstoff verknüpfte glutarimiddegronimere zum zielproteinabbau
WO2018237026A1 (en) 2017-06-20 2018-12-27 C4 Therapeutics, Inc. N / O-LINKED DEGRONS AND DEGRONIMERS FOR DEGRADATION OF PROTEINS
EP3710002A4 (de) 2017-11-16 2021-07-07 C4 Therapeutics, Inc. Degrader und degrone für gezielten proteinabbau
WO2019191112A1 (en) 2018-03-26 2019-10-03 C4 Therapeutics, Inc. Cereblon binders for the degradation of ikaros
CN112312904A (zh) 2018-04-16 2021-02-02 C4医药公司 螺环化合物
WO2020243777A1 (en) 2019-06-03 2020-12-10 Havah Therapeutics Pty Ltd Pharmaceutical formulations and systems for delivery of an androgenic agent and an aromatase inhibitor and methods for use
WO2023014590A1 (en) * 2021-08-05 2023-02-09 Celanese Eva Performance Polymers Llc Implantable medical device for the delivery of bisphosphonate

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4617307A (en) * 1984-06-20 1986-10-14 Ciba-Geigy Corporation Substituted imidazo[1,5-A]pyridine derivatives as aromatase inhibitors
DE3428524A1 (de) * 1984-08-02 1986-02-13 Boehringer Mannheim Gmbh, 6800 Mannheim Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
US4749713A (en) * 1986-03-07 1988-06-07 Ciba-Geigy Corporation Alpha-heterocycle substituted tolunitriles
DE3626058A1 (de) * 1986-08-01 1988-02-11 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
EP0275821B1 (de) * 1986-11-21 1992-02-26 Ciba-Geigy Ag Neue substituierte Alkandiphosphonsäuren

Also Published As

Publication number Publication date
DE60309887D1 (de) 2007-01-04
EP1534265A1 (de) 2005-06-01
EP1534265B1 (de) 2006-11-22
JP2011057706A (ja) 2011-03-24
US20060069067A1 (en) 2006-03-30
DE60309887T2 (de) 2007-05-16
PT1534265E (pt) 2007-02-28
WO2004012728A1 (en) 2004-02-12
CA2494345C (en) 2011-11-29
CA2494345A1 (en) 2004-02-12
ES2276119T3 (es) 2007-06-16
CN100593401C (zh) 2010-03-10
CN1671371A (zh) 2005-09-21
BR0313081A (pt) 2005-07-12
AU2003250190A1 (en) 2004-02-23

Similar Documents

Publication Publication Date Title
ATE345790T1 (de) Kombination von einem aromatasehemmer mit einem bisphosphonat
MX2010006519A (es) Metodo para tratar una fractura de hueso con anticuerpos anti-esclerostina.
BRPI0413255A (pt) uso de uma combinação de um inibidor de quinase do receptor do fator de crescimento epidérmico e agentes citotóxicos para tratamento e inibição do cáncer
WO2004043374A3 (en) Methods and compositions for treating cancer using proteasome inhibitors
DE60030889D1 (de) Verwendung von egfr tyrosine kinase hemmern zur behandlung von brustkrebs
ATE468137T1 (de) Inhibitoren von hmgb1 zur behandlung von gewebekrankheiten
BR0307629A (pt) Métodos e composições para tratar condições hiperproliferativas
HK1080733A1 (en) Pharmaceutical composition for use for the treatment of malignancies comprising in combination a bisphosphonates, a cox-2 inhibitor and a taxol
BRPI0408491A (pt) tratamento da doença de alzheimer
WO2022271810A3 (en) Bicyclic peptidyl pan-ras inhibitors
BR0312929A (pt) Uso de um composto, e, métodos de tratamento, prevenção ou alìvio de uma doença, distúrbio ou condição de um corpo de animal vivo, e da degeneração macular relacionada com a idade de um corpo de animal vivo
EA200501549A1 (ru) Применение экспрессирующего вектора, кодирующего ингибитор il-18, для лечения и/или профилактики заболевания сердца и способ лечения заболевания сердца
WO2002074756A3 (de) Urokinase-inhibitoren
SI1596879T1 (sl) Uporaba spojine kahalalida za pripravo zdravila za zdravljenje luskavice
MXPA05013975A (es) Tratamiento de enfermedades asociadas con amiloide y epileptogenesis.
MXPA01007031A (es) Metodo para tratar enfermedades acrdiacas cronicas.
TNSN06147A1 (en) Use of cathepsin k inhibitors for treating of severe bone loss diseases
DE60334289D1 (de) Dithiolopyrrolon-derivate zur behandlung von proliferativen störungen
HUP9903685A2 (hu) Olanzapin alkalmazása túlzott agresszivitás kezelésére szolgáló gyógyszerkészítmények előállítására
TW200512183A (en) 2-alkylidene-19-nor-vitamin d derivatives for the treatment of frailty, muscle damage or sarcopenia
DE60108775T8 (de) Methode zur behandlung von schlaganfall
TW200511998A (en) 2-alkylidene-19-nor-vitamin d derivatives for the treatment of anorexia or low bone mass in females exhibiting aggressive athletic behavior
BR0315376A (pt) Combinações de benzotiadiazóis e inibidores de cox-2 para o tratamento de dor
MXPA05010216A (es) Uso de ritonavir para el tratamiento de hiperbilirrubinemia no conjugada.
UA67528A (en) Method for surgical treatment of thyroid cancer

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1534265

Country of ref document: EP